Regeneron Pharmaceuticals, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2010. The filing is an annual report, although the request metadata references 2010 Q4. Quarterly fourth-quarter revenue was $133.7 million and net loss was $14.6 million, compared with $96.8 million and $36.5 million, respectively, in the fourth quarter of 2009.
Business Context
Regeneron is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions. ARCALYST was its only marketed product, approved in the United States for CAPS. The pipeline included 11 clinical candidates, including Phase 3 programs for VEGF Trap-Eye, ARCALYST in gout-flare prevention, and aflibercept in oncology.
Regeneron operated as one business segment and relied substantially on collaboration and licensing arrangements, particularly with sanofi-aventis and Bayer HealthCare. The company had 1,395 full-time employees at year-end, including 356 employees at its Rensselaer manufacturing facilities.
Key Financial Metrics
| Metric | 2010 | 2009 | Change |
|---|---|---|---|
| Total revenue | $459.1 million | $379.3 million | Up 21.0% |
| Collaboration revenue | $386.7 million | $314.5 million | Up 23.0% |
| Technology licensing revenue | $40.2 million | $40.0 million | Essentially flat |
| Net product sales | $25.3 million | $18.4 million | Up 37.5% |
| Research and development expense | $489.3 million | $398.8 million | Up 22.7% |
| Total operating expenses | $556.5 million | $453.4 million | Up 22.8% |
| Loss from operations | $97.5 million | $74.1 million | Loss increased |
| Net loss | $104.5 million | $67.8 million | Loss increased 54.0% |
| Basic and diluted loss per share | $1.26 | $0.85 | Loss per share increased |
| Operating margin | Approximately negative 21.2% | Approximately negative 19.5% | Contracted |
| Net margin | Approximately negative 22.8% | Approximately negative 17.9% | Contracted |
| Net cash provided by operating activities | $96.3 million | $(72.2) million | Improved by $168.6 million |
| Capital expenditures | $99.7 million | $97.3 million | Up modestly |
| Cash, cash equivalents and marketable securities | $626.9 million | $390.0 million | Up $236.9 million |
Revenue Mix and Profitability
- Sanofi-aventis collaboration revenue was $311.3 million, including reimbursement of antibody and aflibercept development costs.
- Bayer HealthCare collaboration revenue was $75.4 million and included $20.0 million of substantive milestone payments related to VEGF Trap-Eye.
- ARCALYST net product sales were $25.3 million, including $4.8 million of previously deferred sales recognized after the company accumulated sufficient return and rebate history. The filing states that material product revenue and net cash inflows from CAPS sales were not expected.
- Non-cash stock-based compensation was $39.9 million, compared with $31.3 million in 2009.
- Investment income declined to $2.1 million from $4.5 million, while interest expense increased to $9.1 million from $2.3 million, principally because of facility lease obligations.
Liquidity, Debt and Cash Flow
- Cash, cash equivalents, and marketable securities totaled $626.9 million at December 31, 2010, including $7.5 million of restricted amounts. Marketable securities totaled approximately $513.9 million, primarily consisting of U.S. government and government-guaranteed instruments.
- Operating cash flow was positive principally because of $158.2 million of deferred-revenue increases, including the deferred Astellas payment and sanofi-aventis manufacturing-capacity funding, together with non-cash compensation and depreciation.
- Investing cash flow was $(434.2) million, reflecting $335.6 million of net purchases of marketable securities and $99.7 million of capital expenditures.
- Financing cash flow was $243.3 million, including $174.8 million of net proceeds from an October 2010 common-stock offering and $22.0 million from stock-option exercises.
- The company had no outstanding convertible notes at year-end; its $200.0 million of convertible notes had been fully repaid in 2008. However, facility lease obligations totaled $160.0 million and capital lease obligations totaled $2.8 million.
- Total contractual obligations were $458.1 million, including $250.0 million of facility lease obligations, $108.6 million of purchase obligations, and $96.3 million of operating leases.
- Management stated that existing capital resources and expected collaboration funding were expected to support operating needs through at least 2013, subject to collaboration continuity, revenue, expense, and clinical-development outcomes.
Material Changes Versus 2009
- Revenue increased $79.8 million, driven primarily by higher sanofi-aventis antibody collaboration reimbursement and higher Bayer HealthCare cost sharing and milestones.
- Research and development expense increased $90.4 million, primarily due to increased headcount, clinical-manufacturing costs, antibody programs, VEGF Trap-Eye development, and expanded facilities.
- Average headcount increased to 1,249 from 980; management expected 2011 average headcount of approximately 1,600 to 1,650.
- Net loss increased despite higher revenue because operating expenses grew faster than revenue and interest income declined.
- Deferred revenue increased by $158.2 million, principally from the $165.0 million Astellas upfront payment and sanofi-aventis funding for manufacturing expansion.
- MedImmune, as successor to AstraZeneca, gave notice terminating its VelocImmune license effective February 2011, eliminating the final two scheduled $20.0 million annual payments while preserving potential future royalties.
- Astellas extended its VelocImmune license through June 2023, paid $165.0 million upfront in August 2010, and committed to a potential $130.0 million payment in June 2018, subject to the agreement remaining in effect.
Guidance, Outlook, Risks and Unusual Items
Pipeline and Regulatory Outlook
- Regeneron planned to submit a U.S. BLA for VEGF Trap-Eye in wet AMD in the first half of 2011; Bayer HealthCare planned European regulatory submissions over the same period.
- VIEW 1 and VIEW 2 met their non-inferiority endpoint versus monthly Lucentis at 52 weeks. COPERNICUS produced positive six-month CRVO results, while GALILEO data were expected in the first half of 2011.
- If ongoing studies were successful, management expected to seek approval for ARCALYST in gout-flare prevention by mid-2011 and for aflibercept in one or more oncology indications.
- REGN727 produced dose-dependent LDL reductions in Phase 1 and entered Phase 2 in early 2011. REGN88 was in Phase 2/3 and Phase 2 studies, while REGN910, REGN728, and REGN846 entered early clinical development.
- REGN475 was placed on FDA clinical hold in December 2010 after an avascular-necrosis case in another anti-NGF program raised potential class-effect concerns. No REGN475 trials were enrolling or treating patients.
Principal Risks and Contingencies
- The company had accumulated losses of approximately $1.0 billion since inception and expected substantial operating losses for at least the next several years.
- Clinical and regulatory outcomes remained uncertain; positive early or interim results could fail to translate into approval or commercial success.
- Regeneron depended heavily on sanofi-aventis and Bayer HealthCare for funding, development, regulatory support, manufacturing, and commercialization. Termination or nonperformance could materially increase funding requirements.
- Upon profitability, Regeneron may have to reimburse collaborators for portions of development costs, including approximately half of $707.3 million of aflibercept development expenses and half of $341.0 million of certain antibody-development expenses, subject to contractual formulas and limitations.
- Regeneron filed a declaratory-judgment action against Genentech concerning potential infringement of VEGF Trap-related patents. Genentech moved to dismiss in January 2011; the motion was pending.
- Commercialization faced substantial competition from Lucentis and Avastin in ophthalmology, canakinumab and other IL-1 therapies for ARCALYST, and established or competing therapies in oncology and inflammatory diseases.
- Manufacturing capacity, cGMP compliance, single-source suppliers, third-party fill-finish providers, reimbursement, pricing pressure, intellectual-property challenges, product liability, and adverse events were identified as material risks.
- The filing describes no material off-balance-sheet arrangements other than letters of credit totaling $3.8 million. Internal controls over financial reporting were assessed as effective, with an unqualified auditor opinion.
Investor Verification Checklist
- Verify the sustainability and composition of collaboration revenue, particularly reimbursement-based revenue from sanofi-aventis and milestone revenue from Bayer HealthCare.
- Assess the extent to which the $626.9 million liquidity balance includes restricted funds and deferred or nonrecurring funding sources.
- Review cash-burn expectations excluding the unusually favorable working-capital benefit from increased deferred revenue.
- Monitor 2011 regulatory submissions and outcomes for VEGF Trap-Eye, ARCALYST gout prevention, and aflibercept oncology indications.
- Track the FDA clinical hold and safety developments affecting REGN475.
- Evaluate the Genentech patent litigation and any effect on aflibercept or VEGF Trap-Eye development and commercialization rights.
- Review collaboration termination provisions, contingent reimbursement obligations, and the company’s dependence on sanofi-aventis and Bayer HealthCare.
- Confirm the effect of the AstraZeneca/MedImmune termination on future technology-licensing revenue and the timing of revenue recognition for deferred Astellas payments.